Timothy Dyer - Addex Therapeutics CEO CoFounder
| ADXN Stock | USD 8.71 0.09 1.04% |
Insider
Timothy Dyer is CEO CoFounder of Addex Therapeutics
| Age | 56 |
| Address | Chemin des Mines, 9, Geneva, Switzerland, 1202 |
| Phone | 41 22 884 1555 |
| Web | https://www.addextherapeutics.com |
Addex Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6171) % which means that it has lost $0.6171 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2629) %, meaning that it created substantial loss on money invested by shareholders. Addex Therapeutics' management efficiency ratios could be used to measure how well Addex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to grow to -2.16. In addition to that, Return On Capital Employed is likely to grow to -5.6. At this time, Addex Therapeutics' Intangible Assets are very stable compared to the past year. As of the 29th of November 2024, Other Assets is likely to grow to about 66 K, while Total Assets are likely to drop about 4.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Mark Lappe | Inhibrx | 57 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Susan MS | Eliem Therapeutics | N/A | |
| JD MSc | Cue Biopharma | 61 | |
| MBA MD | Eliem Therapeutics | 63 | |
| James JD | Eliem Therapeutics | 58 | |
| Dr III | Cue Biopharma | 48 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Kenneth MD | Cue Biopharma | 64 | |
| BS CPA | Inhibrx | 42 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| , MBA | Molecular Partners AG | 51 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Steven Almo | Cue Biopharma | 63 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Quinn Deveraux | Inhibrx | N/A | |
Management Performance
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.62 |
Addex Therapeutics Leadership Team
Elected by the shareholders, the Addex Therapeutics' board of directors comprises two types of representatives: Addex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Addex. The board's role is to monitor Addex Therapeutics' management team and ensure that shareholders' interests are well served. Addex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Addex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Dyer, CEO CoFounder | ||
| Werner Henrichi, Consultant | ||
| Mikhail Kalinichev, Head Science | ||
| JeanPhilippe Rocher, Head Chemistry | ||
| Roger MD, Chief Director | ||
| Lnaic Teyssdou, Head Finance | ||
| Robert Lutjens, Head Biology |
Addex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Addex Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | 5.00 % | ||||
| Operating Margin | (7.80) % | ||||
| Current Valuation | 5.35 M | ||||
| Shares Outstanding | 1.07 M | ||||
| Shares Owned By Institutions | 0.16 % | ||||
| Number Of Shares Shorted | 18.42 K | ||||
| Price To Book | 0.74 X | ||||
| Price To Sales | 10.68 X |
Pair Trading with Addex Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Addex Stock
| 0.63 | VTRS | Viatris | PairCorr |
| 0.58 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.45 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.36 | WAT | Waters | PairCorr |
| 0.32 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (21.66) | Revenue Per Share 1.2 | Quarterly Revenue Growth (0.82) | Return On Assets (0.62) | Return On Equity (1.26) |
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.